BeyondAirInc . (NASDAQ: XAIR) is one of 127 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its peers? We will compare BeyondAirInc . to similar businesses based on the strength of its earnings, analyst recommendations, profitability, institutional ownership, dividends, valuation and risk.

Valuation and Earnings

This table compares BeyondAirInc . and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
BeyondAirInc . $7.72 million -$6.56 million -5.83
BeyondAirInc . Competitors $1.43 billion $145.31 million -12.03

BeyondAirInc .’s peers have higher revenue and earnings than BeyondAirInc .. BeyondAirInc . is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.


This table compares BeyondAirInc . and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BeyondAirInc . N/A -342.71% -100.90%
BeyondAirInc . Competitors -674.05% -624.80% -22.23%

Analyst Ratings

This is a summary of recent recommendations and price targets for BeyondAirInc . and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BeyondAirInc . 0 0 0 0 N/A
BeyondAirInc . Competitors 950 3182 5391 284 2.51

As a group, “Surgical & medical instruments” companies have a potential upside of 20.91%. Given BeyondAirInc .’s peers higher possible upside, analysts clearly believe BeyondAirInc . has less favorable growth aspects than its peers.

Institutional and Insider Ownership

5.4% of BeyondAirInc . shares are owned by institutional investors. Comparatively, 51.4% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 15.4% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

BeyondAirInc . has a beta of -0.25, meaning that its share price is 125% less volatile than the S&P 500. Comparatively, BeyondAirInc .’s peers have a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.


BeyondAirInc . peers beat BeyondAirInc . on 7 of the 10 factors compared.

BeyondAirInc . Company Profile

Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory tract infections and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. The company is based in Garden City, New York.

Receive News & Ratings for BeyondAirInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondAirInc . and related companies with's FREE daily email newsletter.